AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01513239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study NCT04435574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100mg sachets.
Study NCT04435574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 6mg/kg of ferrous sulfate.
Study NCT00600743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug one trial vs placebo
Study NCT03537261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)
Description: Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
Study NCT03772743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Culprit-only revascularization
Description: Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
Study NCT03907566 — intervention group
Intervention type: OTHER
Intervention: The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
Description: Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
Study NCT01770353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
Study NCT06688838 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
Study NCT00573131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OncoGel (Paclitaxel gel)
Description: 6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
Study NCT06685926 — intervention group
Intervention type: PROCEDURE
Intervention: Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)
Study NCT06685926 — intervention group
Intervention type: PROCEDURE
Intervention: Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)
Study NCT06694870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous CO2 monitoring
Description: Transuctaneous CO2 monitoring
Study NCT03772743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Complete functionally-guided revascularization
Description: Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
Study NCT04551703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline saline irrigation
Description: The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
Study NCT03851874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery
Study NCT02339389 — intervention group
Intervention type: OTHER
Intervention: Labor analgesia
Description: Measuring maternal ventilation after placement of epidural analgesia compared to baseline
Study NCT02787720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family centered empowerment model
Description: The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
Study NCT02787720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous care model
Description: The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
Study NCT02158624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Lucentis 0.5mg
Study NCT00588003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
Study NCT00588003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No medication before surgery
Study NCT00109928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00109928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00109928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT00109928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00830986 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty Implant (Scorpio®)
Description: Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
Study NCT00830986 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty Implant (Scorpio®)
Description: Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
Study NCT06179589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VS002A
Description: Amino acid based, glucose free ORS
Study NCT06179589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VS002A
Description: Amino acid based, glucose free ORS
Study NCT00573131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV (in the vein) once on Day 1 and Day 29
Study NCT00573131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 IV (in the vein) once on Day 1 and Day 29
Study NCT00573131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
Study NCT00573131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
Study NCT00573131 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
Study NCT00573131 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
Study NCT00573131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal resection
Description: Removal of esophagus after completion of chemotherapy and radiation therapy
Study NCT03763188 — intervention group
Intervention type: OTHER
Intervention: Use of daily urinary urea excretion
Description: Weaning dialysis catheter
Study NCT00573131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: esophageal resection
Description: Removal of esophagus after completion of chemotherapy and radiation therapy
Study NCT03454139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal transversus abdominis plane block
Description: Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
Study NCT01095484 — intervention group
Intervention type: DRUG
Intervention: Rotigotine patch
Description: 1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
Study NCT04370262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC + Intravenous Famotidine
Description: Standard of Care treatment plus IV famotidine
Study NCT04370262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC + Placebo
Description: Standard of Care treatment plus IV placebo
Study NCT01118143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored oral health literacy instruction
Description: The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
Study NCT04912128 — intervention group
Intervention type: DRUG
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
Study NCT03393962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-EIEs
Description: 2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
Study NCT00400387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin P Forte (dalteparin sodium)
Description: subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
Study NCT00400387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Multivitamin supplement
Description: general pregnancy support by multivitamin supplementation and close monitoring
Study NCT03090191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile vaccine
Description: Toxoid-based Clostridium difficile vaccine
Study NCT03090191 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution (0.9% sodium chloride)
Study NCT01251575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT01251575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV
Study NCT01251575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01251575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01251575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01251575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT01251575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01251575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study NCT02253875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)
Study NCT02253875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02253875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT00764894 — intervention group
Intervention type: DEVICE
Intervention: Foundation Knee
Description: Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
Study NCT01174914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ARV's + Placebo
Description: Patients continued ARV's plus a placebo nightly for 9 months
Study NCT01174914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
Study NCT01174914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone + ARV's
Description: Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
Study NCT01399827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Medication
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
Study NCT01399827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADHD Medication
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
Study NCT01399827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
Study NCT02418403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Offer of money designed to overcome barriers to advance care planning.
Study NCT02418403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational website
Description: Research-verson of the Prepare for your care website (www.prepareforyourcare.org)
Study NCT02418403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational website
Description: Research-verson of the Prepare for your care website (www.prepareforyourcare.org)
Study NCT02195115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Study NCT02195115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Study NCT02195115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-fat and low cholesterol diet
Study NCT01331395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chinese Medicine
Description: Active arm will receive Acupuncture with their IVF cycle.
Study NCT04535570 — intervention group
Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
Study NCT02234401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi level pressure support
Study NCT02234401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT04605679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation
Description: A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
Study NCT00003139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilocarpine hydrochloride
Description: 5mg pilocarpine hydrochloride tablets
Study NCT00439179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 1
Description: Weekly gem + GW572016, 1000mg/day (combination)
Study NCT00439179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 2
Description: Weekly gem + GW572016, 1500 mg/day (combination)
Study NCT00439179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 3
Description: GEMOX + GW572016 1000 mg/day (combination)
Study NCT00439179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cohort 4
Description: GEMOX + GW572016 1500 mg/day (combination)
Study NCT03270111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
Study NCT03270111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
Study NCT00003139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02522910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1000394 (Roniciclib) in combination with docetaxel
Description: The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
Study NCT00708877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
Study NCT03270111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Energy Diet
Description: Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
Study NCT03270111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone Calls
Description: Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
Study NCT00994136 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: normal saline
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
Study NCT00994136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
Study NCT04039802 — intervention group
Intervention type: PROCEDURE
Intervention: Single-stage surgery
Description: In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
Study NCT04039802 — intervention group
Intervention type: OTHER
Intervention: Two-stage surgery
Description: Two-stage surgery has already been performed, data will therefore be retrospectively collected
Study NCT00170573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: 40 mg/m² biweekly
Study NCT05586711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal estradiol 10 μg
Description: Vagifem® (estradiol), vaginal tablets
Study NCT05586711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal DHEA 6.5 mg
Description: Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
Study NCT03869736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.